Ron Zimmerman and team may ultimately sell this entire proprietary insulin manufacturing process to one of the Big Three Insulin makers - Lilly, Novo Nordisk, Sanofi.
Whoever buys into his process will make an additional 20% gross profit - plus discount their insulin below the other two Insulin giants prices -